You are now leaving amvuttra.com.
You are now being directed to another Alnylam website.
Proceed CancelRESOURCES
View clinical resources about ATTR
Mechanism of Disease
See how misfolded TTR proteins cause ATTR-CM
Watch the video
This email address is already in use.
Please press Cancel to enter another email, or press Update to receive an email that will allow you to update your preferences.
Email sent!
A link has been sent to your email address.
Modal title
...
You are now leaving ATTR‑Amyloidosis.com
You are now being directed to another Alnylam website.
You are now leaving ATTR‑Amyloidosis.com
Links to all outside
sites are provided as a
reference for our visitors.
Alnylam Pharmaceuticals does
not endorse and is not responsible
for the content on sites that
are not owned and operated by
Alnylam Pharmaceuticals.
THE SITE YOU ARE ABOUT
TO ENTER IS INTENDED FOR
US HEALTHCARE PROFESSIONALS
Are you a
US healthcare professional?
Thank you
Your request has been submitted.
Submitting your request.
This email address is already in use
Email sent!
A link has been sent to your email address.
Title will be here
Lorem Ipsum has been the industry's
Title will be here
Lorem Ipsum has been the industry's
Title will be here
Eyebrow text here
Lorem Ipsum has been the industry's
AL amyloidosis screening2,4
The diagnostic algorithm should always begin with a monoclonal protein screen to assess for AL amyloidosis. If AL amyloidosis is suspected, initiate laboratory testing to assess for monoclonal protein production and evidence of vital organ involvement or dysfunction. In AL amyloidosis, free lambda or free kappa levels are elevated.
